Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Minority-Inclusive Imaging Biomarker-Based End of Therapy Trial for 177Lu-PSMA-617, a Randomized De-Escalation Theranostic Trial for Metastatic Castrate Resistant Prostate Cancer

NCT06200103 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT06200103
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06200103 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Minority-Inclusive Imaging Biomarker-Based End of Therapy Trial for 177Lu-PSMA-617, a Randomized De-Escalation Theranostic Trial for Metastatic Castrate Resistant Prostate Cancer
Lead sponsor
Mayo Clinic
Phase
Phase 2
Overall status
Suspended
Start date
May 3, 2024
Completion date
December 31, 2029
Enrollment
236 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

castration-resistant prostate carcinoma, stage ivb prostate cancer ajcc v8